Achilles Therapeutics PL-ADRACHL
13F holders, Q1 2025 (March 31)6holders −15
1new positions
16sold out
$0.02avg. 13F price*
At the end of Q1 2025, 6 institutions reported holding Achilles Therapeutics PL-ADR (ACHL) in their 13F filings, down 15 from Q4 2024. 1 opened new positions and 16 sold out. The largest holders were XTX Topco Ltd ($58K), Brave Asset Management Inc. ($15K) and Rhumbline Advisers ($7K).
- Company
- Achilles Therapeutics PL-ADR
- CUSIP
- 00449L102
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q4 2024 → Q1 2025
| Institutions | Total Value | |
|---|---|---|
| New Positions | 1 | $1K |
| Exits | 16 | $23.0M |
All 13F filers, Q4 2024 → Q1 2025: 12,905 shares bought and 20,451,557 shares sold, net −20,438,652 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 6 holders
| XTX Topco Ltd | 0.00% | Add +45.1% | 38,923 | $58K |
| Brave Asset Management Inc. | 0.00% | No change | 10,000 | $15K |
| Rhumbline Advisers | 0.00% | No change | 4,480 | $7K |
| GAMMA Investing LLC | 0.00% | New | 806 | $1K |
| SBI Securities Co., Ltd. | 0.00% | Reduce -39.1% | 196 | $290 |
| BML Capital Management, LLC | 0.00% | Reduce -7.2% | 3,804,921 | $0 |
"% of holder's portfolio" is ACHL's weight in each manager's 13F, not the share of Achilles Therapeutics PL-ADR the manager owns.